Dietrich Huppe
Overview
Explore the profile of Dietrich Huppe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Riemann J, Teufel A, Ganslandt T, Hann A, Hildebrandt H, Jutte H, et al.
Z Gastroenterol
. 2021 Jul;
59(5):473-474.
PMID: 34224118
No abstract available.
12.
Simon K, Serfert Y, Buggisch P, Mauss S, Boeker K, Klinker H, et al.
Z Gastroenterol
. 2021 Mar;
59(3):241-249.
PMID: 33684956
Background: Hepatitis C virus (HCV) genotype (GT) 1 is the most common HCV GT in Western and Central Europe. The main focus of this present work is to analyze the...
13.
Huppe D, Niederau C, Serfert Y, Hartmann H, Wedemeyer H
Z Gastroenterol
. 2020 Nov;
58(12):1182-1185.
PMID: 33167051
Background: Healthcare services were faced with unprecedented challenges due to the COVID-19 pandemic and its associated lockdown regulations. In order to analyse the influence of the pandemic on the healthcare...
14.
Graf C, Mondorf A, Knop V, Peiffer K, Dietz J, Friess J, et al.
J Clin Med
. 2019 Dec;
8(12).
PMID: 31810183
Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral...
15.
Mauss S, Buendgens L, Christensen S, Ingiliz P, Berger F, Huppe D, et al.
Z Gastroenterol
. 2019 Feb;
57(2):139-147.
PMID: 30754058
Background And Aims: Disease activity, but also demographics, lifestyle, and comorbidities, may influence alanine aminotransferase (ALT) levels in hepatitis C virus (HCV)-infected patients. Direct-acting antiviral agents (DAA) achieve virological cure...
16.
Huppe D, Serfert Y, Buggisch P, Mauss S, Boker K, Muller T, et al.
Z Gastroenterol
. 2019 Jan;
57(1):27-36.
PMID: 30641600
Background: More than 250 000 patients suffer from chronic hepatitis C in Germany. Several potent, direct-acting antiviral drugs have been approved since 2014. The aim of the German Hepatitis C-Registry...
17.
Knop V, Hofmann W, Buggisch P, Klinker H, Mauss S, Gunther R, et al.
J Viral Hepat
. 2018 Oct;
26(2):224-230.
PMID: 30315694
Treatment decisions are based on extent of fibrosis in patients with chronic hepatitis C (HCV) infection. Noninvasive diagnostic tools may help to avoid liver biopsy. We investigated the diagnostic accuracy...
18.
Dultz G, Muller T, Petersen J, Mauss S, Zimmermann T, Muche M, et al.
Drugs Aging
. 2018 Aug;
35(9):843-857.
PMID: 30084012
Background: With the aging of the hepatitis C virus (HCV)-infected patient cohort and the availability of highly effective and tolerable treatment regimens, an increasing number of elderly patients are now...
19.
Maasoumy B, Buggisch P, Mauss S, Boeker K, Muller T, Gunther R, et al.
Liver Int
. 2018 Jul;
38(11):1906-1910.
PMID: 30022590
Background & Aims: AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with...
20.
Honer Zu Siederdissen C, Buggisch P, Boker K, Schott E, Klinker H, Pathil A, et al.
United European Gastroenterol J
. 2018 Mar;
6(2):213-224.
PMID: 29511551
Background: In pivotal studies with direct-acting antivirals (DAAs), rates of sustained virological response in hepatitis C genotype 1 infection are >90%. Objective: The objective of this article is to assess...